Have Insiders Been Selling Ajanta Pharma Limited (NSE:AJANTPHARM) Shares This Year?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you buy or sell Ajanta Pharma Limited (NSE:AJANTPHARM), you may well want to know whether insiders have been buying or selling.

What Is Insider Buying?

Most investors know that it is quite permissible for company leaders, such as directors of the board, to buy and sell stock on the market. However, such insiders must disclose their trading activities, and not trade on inside information.

Insider transactions are not the most important thing when it comes to long-term investing. But equally, we would consider it foolish to ignore insider transactions altogether. As Peter Lynch said, ‘insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.’

Check out our latest analysis for Ajanta Pharma

The Last 12 Months Of Insider Transactions At Ajanta Pharma

Over the last year, we can see that the biggest insider sale was by the , R. Shelke, for ₹6.3m worth of shares, at about ₹1,256 per share. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. The good news is that this large sale was at well above current price of ₹960. So it may not tell us anything about how insiders feel about the current share price.

Over the last year, we note insiders sold 8600 shares worth ₹10m. In the last year Ajanta Pharma insiders didn’t buy any company stock. You can see a visual depiction of insider transactions (by individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

NSEI:AJANTPHARM Recent Insider Trading, June 17th 2019
NSEI:AJANTPHARM Recent Insider Trading, June 17th 2019

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Ajanta Pharma Insiders Are Selling The Stock

The last three months saw some Ajanta Pharma insider selling. Jeffrey William only netted ₹1.0m selling shares, in that period. Neither the lack of buying nor the presence of selling is heartening. But the amount sold isn’t enough for us to put any weight on it.

Insider Ownership of Ajanta Pharma

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. It’s great to see that Ajanta Pharma insiders own 60% of the company, worth about ₹50b. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Do The Ajanta Pharma Insider Transactions Indicate?

An insider hasn’t bought Ajanta Pharma stock in the last three months, but there was some selling. And there weren’t any purchases to give us comfort, over the last year. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn’t make us feel confident about the company. Of course, the future is what matters most. So if you are interested in Ajanta Pharma, you should check out this free report on analyst forecasts for the company.

Of course Ajanta Pharma may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.